The role of adjuvant immunotherapy in renal cell carcinoma

Current Urology Reports

Volumn 3, Issue 1, 2002, Pages 44-49

  Mulders, Peter F A ^a   de Mulder, Pieter H M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Advanced Renal Cell Carcinoma; Clin Oncol; Metastatic Renal Cell Carcinoma; Radical Nephrectomy; Renal Cell Carcinoma

Indexed keywords

TUMOR MARKER;

BLOOD; CANCER INVASION; CANCER STAGING; HUMAN; IMMUNOTHERAPY; KIDNEY CARCINOMA; KIDNEY TUMOR; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; REVIEW;

CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0036484438     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-002-0010-y     Document Type: Article

References (46)

1. Garnick MB, Richie JP: Renal neoplasia. In The Kidney. Edited by Brenner BM, Rector FC Jr. Philadelphia: WB Saunders Co.; 1991:1809–1827.
2. Parker SL, Tong T, Bolden S et al.: Cancer statistics, 1997. CA Cancer J Clin 1997, 47:5–27.
3. Katz DL, Zheng T, Holford TR, et al.: Time trends in the incidence of renal carcinoma: analysis of Connecticut Tumor Registry data, 1935–1989. Int J Cancer 1994, 58:57–63. DOI: 10.1002/ijc.2910580111
4. McDougal WS, Garnick MB: Clinical signs and symptoms of renal cell carcinoma. In Comprehensive Textbook of Genitourinary Oncology. Edited by Vogelzang NJ, Scardino PT, Shipley WU, et al. Baltimore: Williams & Wilkins 1996:154–159.
5. Waters WB, Richie JP: Aggressive surgical approach to renal cell carcinoma: review of 130 cases. J Urol 1979, 122:306–309.
6. Golimbu M, Joshi P, Sperber A, et al.: Renal cell carcinoma: survival and prognostic factors. Urology 1986, 27:291–301. DOI: 10.1016/0090-4295(86)90300-6
7. Kozlowski JM: Surgical resection of metastatic disease. In Comprehensive Textbook of Genitourinary Oncology. Edited by Vogelzang NJ, Scardino PT, Shipley WU, et al. Baltimore: Williams & Wilkins 1996:284–292.
8. Sigel A, Chlepas S., Schrott KM, Hermanek P: Surgery of the kidney tumor [in German]. Surgeon 1981, 52:545–553.
9. Pizzocaro G, Piva L: Pros and cons of retroperitoneal lymphadenectomy in operable renal cell carcinoma. Eur Urol 1990, 18(suppl 2):22–23.
10. Porzsolt F: Adjuvant therapy of renal cell cancer with interferon-alpha 2a. Delta-p gruppe. Proc Am Soc Clin Oncol 1992, 11:202.
11. Herrlinger A, Schrott KM, Schott G, Sigel A: What are the benefits of extended dissection of the regional renal lymph nodes in the therapy of renal cell carcinoma. J Urol 1991, 146:1224–1227.
12. Blom JH, van Poppel H, Marechal JM, et al.: Radical nephrectomy with and without lymph node dissection: preliminary results of the EORTC randomized phase III protocol 30881. EORTC Genitourinary Group. Eur Urol 1999, 36:570–575. DOI: 10.1159/000020050
13. Zisman A, Pantuck AJ, Dorey F, et al.: Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 2001, 19:1649–1657. This article refocuses our interest in the prognostic factor analysis of RCC. It may help in appropriate selection of patients for adjuvant protocols.
14. Van Poppel H, Vandendriessche H, Boel K, et al.: Microscopic vascular invasion is the most relevant prognosticator after radical nephrectomy for clinically nonmetastatic renal cell carcinoma. J Urol 1997, 158:45–49. This article is an example of the detection of a new and independent prognostic factor. Microvascular invasion became an inclusion criteria for at-risk patients for recurrent disease after tumor nephrectomy in the European Organization for Research and Treatment of Cancer adjuvant protocol. DOI: 10.1097/00005392-199707000-00013
15. Katagiri A, Watanabe R, Tomita Y: E-cadherin expression in renal cell cancer and its significance in metastasis and survival. Br J Cancer 1995, 71:376–379.
16. Nouwen EJ, Dauwe S, van der Biest I, De Broe ME: Stage- and segment-specific expression of cell-adhesion molecules N-CAM, A-CAM, and L-CAM in the kidney. Kidney Int 1993, 44:147–158. DOI: 10.1038/ki.1993.225
17. Shimazui T, Oosterwijk E, Debruyne FM, Schalken JA: Molecular prognostic factor in renal cell carcinoma. Semin Urol Oncol 1996, 14:250–255.
18. Grabmaier K, Vissers JL, De Weijert MC, et al.: Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. Int J Cancer 2000, 85:865–870. DOI: 10.1002/(SICI)1097-0215(20000315)85:6<865::AID-IJC21>3.0.CO;2-Q
19. Murakami Y, Kanda K, Tsuji M, et al.: MN/CA9 gene expression as a potential biomarker in renal cell carcinoma. BJU Int 1999, 83:743–747. DOI: 10.1046/j.1464-410x.1999.00007.x
20. Yagoda A, Petrylak D, Thompson S: Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am 1993, 20:303–321.
21. Heinzer H, Huland E, Huland H: Systemic chemotherapy and chemoimmunotherapy for metastatic renal cell cancer. World J Urol 2001, 19:111–119. DOI: 10.1007/s003450000191
22. Mulders P, Figlin R, deKernion JB, et al.: Renal cell carcinoma: recent progress and future directions. Cancer Res 1997, 57:5189–5195. This article gives an overview on the current status of more specific immuno-and gene therapy approaches in RCC treatment. It implements translational research projects in this field.
23. Atzpodien J, Kirchner H, Hanninen EL, et al.: European studies of interleukin-2 in metastatic renal cell carcinoma. Semin Oncol 1993, 20(suppl 9):22–26.
24. van Herpen CM, Jansen RL, Kruit WH, et al.: Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party. Br J Cancer 2000, 82:772–776. DOI: 10.1054/bjoc.1999.0997
25. Motzer RJ, Murphy BA, Bacik J, et al.: Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 2000, 18:2972–2980.
26. Stadler WM, Kuzel T, Dumas M, Vogelzang NJ: Multicenter phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma. J Clin Oncol 1998, 16:1820–1825.
27. Pizzocaro G, Piva L, Colavita M, et al.: Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol 2001, 19:425–431. This article describes one of the few protocols in adjuvant treatment of RCC. It includes the problems of adequate selection and follow-up of this patient category. Also, the toxicity of immunotherapy with dose reduction becomes clear.
28. Trump DL, Elson P, Propert K et al.: Randomized, controlled trial of adjuvant therapy with lymphoblastoid interferon in resected, high risk renal cell carcinoma: an ECOG study [abstract 648]. Proc Am Soc Clin Oncol 1996, 15:253.
29. Mule JJ, Ettinghausen SE, Spiess PJ et al.: Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy. Cancer Res 1986, 46:676–683.
30. Debruyne FM, Franssen MP, Beniers AJ, et al.: New prospects in the management of metastatic renal cell carcinoma. Experimental and clinical data. Prog Clin Biol Res 1990, 350:243–255.
31. Fisher RI, Coltman CA, Doroshow JH et al.: Metastatic renal cancer treated with interleukin-2 and lymphokineactivated killer cells: a phase II clinical trial. Ann Intern Med 1988, 108:518–523.
32. Jayson GC, Middleton M, Lee SM, et al.: A randomized phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer. Br J Cancer 1998, 78:366–369.
33. Elias L, Lew D, Figlin RA, et al.: Infusional interleukin-2 and 5-fluorouracil with subcutaneous interferon-alpha for the treatment of patients with advanced renal cell carcinoma: a southwest oncology group Phase II study. Cancer 2000 89:597–603. DOI: 10.1002/1097-0142(20000801)89:3<597::AID-CNCR15>3.0.CO;2-E
34. Negrier S, Caty A, Lesimple T, et al.: Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Francais d’Immunotherapie, Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 2000, 18:4007–4008.
35. Figlin RA, Thompson JA, Bukowski RM, et al.: Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol 1999, 17:2521–2529.
36. Köhler G, Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity. 1975. Biotechnology 1992, 24:524–526.
37. Steinman RM, Young JW: Signals arising from antigenpresenting cells. Curr Opin Immunol 1991, 3:361–372. DOI: 10.1016/0952-7915(91)90039-4
38. Kiertscher S, Roth M: Human CD14+ leukocytes acquire the phenotype and function of antigen-presenting dendritic cells when cultured in GM-CSF and IL-4. J Leukocyte Biol 1996, 59:208–218.
39. Sallusto F, Lanzavecchia A: Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macropgage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994, 179:1109–1118. DOI: 10.1084/jem.179.4.1109
40. Inaba K, Metlay JP, Crowley MT, et al.: Dendritic cells as antigen presenting cells in vivo. Int Rev Immunol 1990, 6:197–206.
41. Huang M, Golumbek P, Ahmadzadeh M, et al.: Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994, 264:961–965. DOI: 10.1126/science.7513904
42. Freudenthal PS, Steinman RM: The distinct surface of human blood dendritic cells, as observed after an improved isolation method. Proc Natl Acad Sci U S A 1990, 87:7698–7702. DOI: 10.1073/pnas.87.19.7698
43. Flamand V, Sornasse T, Thielemans K, et al.: Murine dendritic cells pulsed in-vitro with tumor antigens induce tumor resistance in-vivo. Eur J Immunol 1994, 24:605–610. DOI: 10.1002/eji.1830240317
44. Mayordomo JI, Zorina T, Storkus WJ, et al.: Bone marrowderived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumor immunity. Nature Med 1995, 1:1297–1302. DOI: 10.1038/nm1295-1297
45. Hsu FJ, Benike C, Fagnoni F, et al.: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med 1996, 2:52–58. DOI: 10.1038/nm0196-52
46. Storkus WJ, Zeh HJ III, Salter RD, Lotze MT: Identification of T-cell epitopes: rapid isolation of class I-presented peptides from viable cells by mild acid elution. J Immunother 1993, 14:94–103. DOI: 10.1097/00002371-199308000-00003